11:40 AM
Jan 26, 2018
 |  BC Week In Review  |  Company News  |  Deals

Taiwan Liposome forms JV with Jixi in China

Taiwan Liposome Co. Ltd. (TPEx:4152) said it entered into a joint venture with Jixi Biotechnology to promote and market Taiwan Liposome's drugs more efficiently in China.

Jixi will invest $20 million to purchase a partial stake in TLC Biopharmaceuticals (H.K.) Ltd., a Hong Kong subsidiary of Taiwan Liposome, through which Taiwan Liposome's products...

Read the full 250 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >